Wertigkeit von systemischen alpha-Synuklein-Ablagerungen in der Diagnostik des idiopathischen Parkinson-Syndroms – Pro

Einleitung

Das idiopathische Parkinson-Syndrom zählt zu den häufigsten neurodegenerativen Erkrankungen mit Prävalenzen im europäischen Raum von mehr als 1 % bei über 65-Jährigen [1]. Der in Studien belegte Nutzen einer frühzeitigen Erkennung und verlaufsorientierten individualisierten Behandlung sowie die immer noch zu weiten Teilen ungeklärte Ätiopathogenese der Erkrankung verdeutlicht den Bedarf an neuen Biomarkern und diagnostischen Verfahren [2] [3]. Alpha-Synuklein ist ein pathophysiologisch bedeutsames Protein, welches das idiopathische Parkinson-Syndrom (Morbus Parkinson) charakterisiert und daher einen hilfreichen Marker zur Unterscheidung dieser Erkrankung von anderen neurodegenerativen Erkrankungen mit Parkinson-ähnlicher klinischer Manifestation, die durch abnormales Protein Tau charakterisiert sind (zum Beispiel: kortikobasale Degeneration, progressive supranukleäre Paralyse), darstellt.

• Literatur

• 1 von Campenhausen S, Bornschein B, Wick R et al. Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol 2005; 15: 473-490
• 2 Ossig C, Reichmann H. Treatment strategies in early and advanced Parkinson disease. Neurol Clin 2015; 33: 19-37
• 3 Saracchi E, Fermi S, Brighina L. Emerging candidate biomarkers for Parkinson’s disease: a review. Aging Dis 2013; 5: 27-34
• 4 Maroteaux L, Campanelli JT, Scheller RH. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 1988; 8: 2804-2815
• 5 Murphy DD, Rueter SM, Trojanowski JQ et al. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. Neurosci 2001; 20: 3214-3220
• 6 Abeliovich A, Schmitz Y, Fariñas I et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000; 25: 239-252
• 7 Fujiwara H, Hasegawa M, Dohmae N. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002; 4: 160-164
• 8 Hong Z, Shi M, Chung KA et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain 2010; 133: 713-726
• 9 Olanow CW, McNaught K. Parkinson’s disease, proteins, and prions: milestones. Mov Disord 2011; 26: 1056-1071
• 10 Halliday G, Lees A, Stern M. Milestones in Parkinson’s disease – clinical and pathologic features. Mov Disord 2011; 26: 1015-1021
• 11 Wang N, Gibbons CH, Lafo J et al. α-Synuclein in cutaneous autonomic nerves. Neurology 2013; 81: 1604-1610
• 12 Siepmann T, Penzlin AI, Illigens BMW. Autonomic neuropathies. Dtsch Med Wochenschr 2013; 138: 1465-1469
• 13 Low PA, Caskey PE, Tuck RR et al. Quantitative sudomotor axon reflex test in normal and neuropathic subjects. Ann Neurol 1983; 14: 573-580
• 14 Freeman R. Autonomic peripheral neuropathy. Lancet 2005; 365: 1259-1270
• 15 Siepmann T, Illigens BM, Reichmann H et al. Axon-reflex based nerve fiber function assessment in the detection of autonomic neuropathy. Der Nervenarzt 2014; 85: 1309-1314
• 16 Siepmann T, Gibbons C, Lafo J et al. Quantitative Pilomotor Axon-Reflex Test – A Novel Test of Pilomotor Function. Arch Neurol 2012; 6: 1-5
• 17 Illigens BM, Siepmann T, Roofeh J et al. Laser-doppler imaging in the detection of peripheral neuropathy. Auton Neurosci 2013; 177: 286-290
• 18 Kawada M, Tamada Y, Simizu H. Reduction in QSART and vasoactive intestinal polypeptide expression in the skin of Parkinson’s disease patients and its relation to dyshidrosis. J Cutan Pathol 2009; 36: 517-521
• 19 Doppler K, Ebert S, Uçeyler N et al. Cutaneous neuropathy in Parkinson’s disease: a window into brain pathology. Acta Neuropathol 2014; 128: 99-109
• 20 Donadio V, Incensi A, Leta V et al. Skin nerve α-synuclein deposits: a biomarker for idiopathic Parkinson disease. Neurology 2014; 82: 1362-1369
• 21 Wakabayashi K, Mori F, Tanji K et al. Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain. Acta Neuropathol 2010; 120: 1-12
• 22 Tokuda T, Salem SA, Allsop D et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. Biochem Biophys Res Commun 2006; 349: 162-166
• 23 Mollenhauer B, Cullen V, Kahn I et al. Direct quantification of CSF alpha-synuclein by ELISA and first crosssectional study in patients with neurodegeneration. Exp Neurol 2008; 213: 315-325
• 24 Öhrfelt A, Grognet P, Andreasen N et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders – a marker of synapse loss?. Neurosci Lett 2009; 450: 332-335
• 25 Parnetti L, Castrioto A, Chiasserini D. Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol 2013; 9: 131-140
• 26 Unterberger U, Lachmann I, Voigtänder T. Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study. Clin Neuropathol 2014; 33: 329-334
• 27 Adler CH, Dugger BN, Hinni ML et al. Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology 2014; 82: 858-864
• 28 Al-Nimer MS, Mshatat SF, Abdulla HI. Saliva α-synuclein and a high extinction coefficient protein: a novel approach in assessment biomarkers of Parkinson’s disease. N Am J Med Sci 2014; 6: 633-637